Meet the Team

Tom founded HSRL, now StageBio, in 1999 with the goal of supporting other CROs, government and academic researchers and anyone interested in drug discovery. As CEO and Laboratory Director, Tom oversees both the business operations and the laboratory services division of StageBio. Under Tom’s leadership, the company has processed tissues from more than 1,500 GLP studies, including toxicologic, neurotoxicity, reproductive, inhalation, sub-chronic and carcinogenicity studies. Tom was educated at James Madison University.

Carrie joined HSRL, now StageBio, in 2006 to manage all areas of the Pathology Services division. Now as Senior Vice President of Client Relations, Carrie serves as an essential liaison between StageBio and its clients. Carrie plays a key role on the executive leadership team, utilizing her expertise from her previous role as the Director of Pathology Services in which she was responsible for coordinating all pathology deliverables and deadlines among the pathologists, the pathology support team and clients. Carrie's comprehensive experience as a project manager, prior to and during her current career, make her extremely well-suited to manage many of the daily operations at StageBio. Carrie earned her Associate of Arts degree from Frederick Community College and subsequently continued her education at Mount Saint Mary’s University.

Sam has more than 14 years of experience working in biological specimen storage, and in the preclincial research industry. As Director of Corporate Development for StageBio, he will oversee the long-term integrity of GLP materials and connect with clients regarding their needs and servcies. Sam is well-versed in industry best practices and regulations for specimen retention and environmental controls. He was also a founder and owner of HSRL Archives, LLC from 2005 – 2019. Sam received his BS from James Madison University.

Chris received his BS degree in Biology from Virginia Tech in 1993, and his MS degree in Pathobiology from the Bowman Gray School of Medicine at Wake Forest University in 1999. He served as a Division Manager for Pathology Associates International from 1999 to 2001, and then with Charles River Laboratories from 2001 to 2005. Chris was co-founder and co-owner of Vet Path Services and VPS Archives from 2005 to 2018. He currently serves as the Client Ambassador for StageBio.

Dr. Knostman is a toxicologic and diagnostic pathology expert, having served as lead pathologist in hundreds of preclinical studies for industry and government clients. Her expertise spans multiple species, dose routes and study designs, from small dose-range-finding pilot studies to large two-year carcinogenicity assays; vaccine and biologic efficacy and safety pharmacology studies to medical device pathology and chemical agent exposure models. She is also experienced in immunohistochemistry.

Dr. Knostman earned her DVM from The Ohio State University in 2000, completing her residency in Anatomic Pathology and receiving her PhD from The Ohio State University in 2007. She became a Diplomate of the American College of Veterinary Pathologists in 2007.

Dr. Hutto has supported academic institutions, pharmaceutical and biotechnology companies with non-clinical veterinary pathology expertise, leveraging experience in study design, animal model selection and evaluation, and data interpretation for GLP and non-GLP studies. As Director of Investigative Pathology for StageBio, Dr. Hutto uses specialty investigative techniques, including immunohistochemistry, immunofluorescence, and morphometry. Dr. Hutto earned her DVM from Tufts University School of Veterinary Medicine in 1994 and became a Diplomate of the American College of Veterinary Medicine in 2001. In 2004, she earned her PhD from the University of Connecticut.

Dr. Butt has more than 20 years of experience evaluating the nervous system in a wide variety of laboratory species. As the principal investigator/study neuropathologist of over 500 preclinical investigations, Dr. Butt has consulted with global pharmaceutical and histopathology companies and is a regulatory consultant on matters concerning the nervous system. He is a frequent speaker at national/international meetings, educational symposiums, and FDA sponsored events. Prior to joining StageBio, Dr. Butt was founder and president of Tox Path Specialists, a national leader in the field of neuropathology. Previous to this, he managed the Charles River Laboratories - Frederick, MD division, providing professional oversight for over 200 employees and 35 veterinary pathologists.

Dr. Jackson specializes in medical device pathology, with primary interests in orthopedic, wound healing,ocular, gastrointestinal, and cardiovascular devices. Prior to StageBio, Dr. Jackson worked for AccelLAB and Alizee Pathology. She has authored multiple peer-reviewed publications and is the Co-Chair for the STP Medical Device SIG. Dr. Jackson received her BS (Biological Engineering) and DVM from Kansas State University, and completed her anatomic residency through the Texas A&M University Cardiovascular Pathology Laboratory, with board certification (ACVP) in 2013.

Dr. Garlick’s wide-ranging experience in drug discovery and preclinical development spans nearly three decades. He has evaluated an extensive variety of compounds in numerous species, with specialized expertise in the histopathology of minipigs, animal models of disease, evaluation of biomaterials and ocular pathology. Additionally, he is an adjunct professor and affiliate member of the Cancer Center at The Wistar Institute in Philadelphia.

Dr. Garlick earned his DVM from Tufts University School of Veterinary Medicine in 1985 and completed his pathology residency training at Tufts in 1989. He became a Diplomate of the American College of Veterinary Pathologists in 1990.

Dr. Buccellato has supported a wide variety of research animal species in dose range-finding, sub-chronic and chronic studies. He has served as lead pathologist for pharmaceutical efficacy and preclinical toxicity studies and has extensive experience aiding the development of therapies for a number of bacterial and viral pathogens and chemical agents.

Dr. Buccellato earned his DVM from North Carolina State University in 2001, then completed his residency in Anatomic Pathology and received his Ph.D. from The Ohio State University in 2008. He became a Diplomate of the American College of Veterinary Pathologists in 2008.

Dr. Cramer has over 10 years of experience in the field of veterinary anatomic pathology and has spent the several years focusing on toxicologic neuropathology. As principal investigator or study pathologist, Dr. Cramer has read dozens of neurotoxicity studies and frequently consults with companies and clients regarding study design and approaches. Prior to joining StageBio, Dr. Cramer worked at Tox Path Specialists as a Senior Research Pathologist. Dr. Cramer completed graduate training at the National Cancer Institute as a part of the Comparative Biomedical Scientist Training Program (National Institutes of Health). Before graduate training, Dr. Cramer completed a residency in anatomic pathology at Oklahoma State University, and attended the Cornell College of Veterinary Medicine.

Dr. Crissman has conducted a wide range of studies for our clients, from transgenic mice to dairy cows. Previously, he worked in drug development for ICI Pharmaceuticals, industrial and agricultural chemical safety for Dow Chemical and Corning, and veterinary medicine for a mostly dairy practice. He has served on committees for the ACVP and STP, was the review editor for Veterinary Pathology, and editor and columnist for the STP newsletter. He has authored more than 30 scientific papers and book chapters.

Dr. Crissman earned a BS and DVM from Michigan State University in 1973 and 1977, respectively. He became a member of the American College of Veterinary Pathologists in 1984 and earned his PhD in Veterinary Pathology from Cornell University in 1986.

Dr. Elcock has more than 30 years of experience as a toxicologic veterinary pathologist, serving as the primary study pathologist for 500-plus GLP preclinical studies in the pharmaceutical and agricultural industries. She has a particular interest in reproductive pathology and has evaluated more than 15 peer-reviewed carcinogenicity studies in a variety of mouse and rat strains.

Dr. Elcock earned her DVM in 1982, as well as her MS and PhD in Veterinary Pathology in 1983 and 1985, respectively, all from Kansas State University. She became a Diplomate of the American College of Veterinary Pathologists in 1987.

Dr. Farman has over 20 years of experience in toxicologic pathology, including in contract research laboratory (Charles River) and biotechnology (Genentech) companies, and as an independent pathology consultant/contractor (Farman Pathology). She has a specialty interest and expertise in ocular pathology. Dr. Farman has experience with a wide variety of compound types and laboratory species, and has interacted with a large number of scientists from biotechnology and pharmaceutical companies.She completed her DVM and PhD at UC Davis in 1988 and 1999, respectively, and became a Diplomate of the American College of Veterinary Pathologists in 1994.

Dr. Hutt’s experience spans multiple animal species, including mice, rats, cotton rats, rabbits, dogs, ferrets, minipigs and primates. Prior to StageBio, she served as study pathologist for the Lovelace Respiratory Research Institute (LRRI), conducting a wide range of GLP and non-GLP safety toxicology studies, with an emphasis on inhalational toxicology and gene therapy.

Dr. Hutt earned her BS and MS in chemistry from The Ohio State University, and worked as a laboratory chemist prior to attending veterinary school. She earned her DVM in 1993 and completed a combined residency program in anatomic pathology and veterinary biosciences at The Ohio State University, earning her PhD in 2002. She has been a member of the American College of Veterinary Pathologists since 2001.

Dr. Lanigan earned her DVM and PhD from The Ohio State University, and is a Diplomate of the American College of Veterinary Pathologists (ACVP). She has been active as a boarded Veterinary Pathologist in the commercial preclinical industry since 2015. As a member of multiple societies, Dr. Lanigan is particularly active in her memberships with ACVP and the Society of Toxicologic Pathology (STP). Currently, she serves as co-chair of the STP special interest group in neuropathology (SIGN). StageBio is delighted to add her general toxicity experience to our group, as well as her special interest in neuropathology/neurotoxicology.

Dr. Morgan’s professional interests include the use of animal models of disease in drug development. Prior to joining StageBio, she worked at Abbott/AbbVie and provided pathology support across multiple therapeutic indications. She has authored numerous peer-reviewed publications. Dr. Morgan received her DVM from Kansas State University (1980), and her PhD in pathology from Texas A&M University (1988). She is a Diplomate of the American College of Veterinary Pathologists, the American Board of Toxicology, and the American Board of Veterinary Toxicology.

Prior to joining StageBio, Dr. Neu spent 15 years in drug safety assessment at P&G, where she also supervised histology and necropsy services. Earlier in her career, she was a diagnostic pathologist at Breathitt Veterinary Center of Murray State University, where she gained extensive experience in large animal pathology.

Dr. Neu received her BS and DVM from the University of Minnesota in 1975 and 1979, respectively, and her PhD in pathology from the University of Kentucky in 1988. She has been a member of the American College of Veterinary Pathologists since 1991.

Dr. Paulman specializes in animal models of autoimmune disease, cancer drug development, neuropathology and male reproductive toxicity. Prior to joining StageBio, she worked at Covance, where she focused on non-GLP early-stage toxicology and investigational studies. Earlier, she provided pathology support to multiple drug development project teams at Eli Lilly and Co.

Dr. Paulman received her DVM in 1998 and her PhD in pathology in 2006, both from the University of Illinois. She is a diplomate of the American College of Veterinary Pathologists in anatomic pathology.

Dr. Saladino has over 20 years of experience in veterinary pathology, and has completed over 250 studies including non-GLP and GLP safety assessment, animal models of human disease, radiation exposure models, medical device studies, and carcinogenicity assays in transgenic mice. She has worked at three other contract labs, with 11 years in management. She serves on the Board of Directors for the Charles Louis Davis and Samuel Wesley Thompson DVM Foundation. Dr. Saladino earned her DVM from the University of Wisconsin in 1992, then served in the Army Veterinary Corps for 10 years. She completed a pathology residency at the Armed Forces Institute of Pathology, and became a Diplomate of the American College of Veterinary Pathologists in 1999.

Dr. Sharpnack’s expertise spans GLP pharmaceutical, animal health and medical device anatomic and clinical pathology. Prior to StageBio, he worked at Pathology Associates International, Charles River Laboratories and held roles of increasing responsibility at CDC, including representative to the National Toxicology Program and charter member of the Interagency Committee for the Validation of Alternative Methods. He has published 12 peer-reviewed publications, several book chapters and a number of regulatory documents.

Dr. Sharpnack attended The Ohio State University, where he received his BS in 1977 and his MS and DVM in 1981. He was a veterinary officer in the US Army from 1981-1991, during which time he trained in anatomical pathology at the Walter Reed Army Institute of Research. He has been a diplomate of the American College of Veterinary Pathologists since 1989.

Dr. Sullivan has more than 25 years of experience in small and large molecule study interpretation, peer and management review, and toxicity risk assessment. Prior to StageBio, he held roles of increasing responsibility at Eli Lilly and Co., conducting discovery and GLP risk assessment of preclinical in vivo and in vitro across several therapeutic areas. Earlier, he was a GLP study director at Marion Merrell Dow/Dow Chemical Co. and a study pathologist and study director at Abbott Laboratories.

Dr. Sullivan received a BS and DVM from Mississippi State University in 1977 and 1981, respectively, an MS in toxicology from the University of Illinois in 1988, and a PhD in Pathology from Purdue University in 1992. He has been a diplomate of the American Board of Veterinary Toxicology since 1990 and a diplomate of American College of Veterinary Pathologists since 1994.

Dr. Young’s professional interests include cancer drug development, neuropathology and female reproductive toxicity. Prior to StageBio, she worked at Covance, where she concentrated on non-GLP early-stage toxicology and investigational studies. Earlier, she worked at Eli Lilly and Co., where she provided pathology support for multiple drug development project teams. She has authored numerous peer-reviewed publications and was formerly Chair of the STP/ASCVP Clinical Pathology in Carcinogenicity Studies Working Group.

Dr. Young received her DVM from Iowa State University in 1988, and her PhD in pathology from Colorado State University in 1998. She is a diplomate of the American College of Veterinary Pathologists and double boarded in both anatomic and clinical pathology.

Scott runs the day-to-day archiving activities at StageBio, working in close collaboration with archiving technicians, vendors and lab personnel. He is responsible for timely client communication and ensuring all areas of the archives are running efficiently. He has been with the company for more than three years and has a comprehensive understanding of small business operations and customer service.

Scott has a BBA in management from James Madison University.

Jim has more than six years of experience in archiving services, having served as Archive Technician before becoming the Archivist for StageBio Archives. As the main point of contact for our clients, his primary responsibilities include the oversight of daily archive business operations and staff, customer relations, material management, contract review and generation of cost proposals.

Vicky has over 10 years of experience in preclinical research, and began her career in quality assurance in 2007. As Director of Quality Assurance for StageBio, she is responsible for overseeing all aspects of the company’s QAU, including GLP training, performance of audits and vendor inspections, conducting audits and hosting both client and regulatory audits. She earned her RQAP-GLP certification in 2014.

Vicky earned a BS in animal and poultry sciences from Virginia Polytechnic and State University in 2004.

Karen has more than 15 years of experience in report writing and publishing of non-clinical regulatory submissions, supply chain management, package development, technical support activities, preparation of pathology reports and regulatory dossier audits. As Quality Assurance Manager for StageBio, she is responsible for providing quality assurance and regulatory compliance services with regard to applicable FDA, EPA, and OECD Good Laboratory Practices.

Karen received her BA from The Ohio State University in 1987.

Craig is an integral part of our team's success. As Senior Director of Laboratory Operations for StageBio, he oversees the day-to-day operations of the laboratory, ensuring all studies are processed accurately and efficiently.

Craig received his BSc from Eastern Mennonite University.

Sheree has more than 30 years of experience in histology, quality control, regulatory compliance services (US FDA, EPA and OECD Good Laboratory Practices) and laboratory management. From 2005 to 2018, she was a co-owner of Vet Path Services, Inc., which is now StageBio.

Sheree received her Associate’s Degree in Animal Science from the University of Cincinnati in 1984 and her certification in histology from the American Society for Clinical Pathology (ASCP) in 1987.

Renee is a proven administrator with more than 25 years of experience in a variety of industries, affording her a strong working knowledge of finance, business administration and human resources. As Accounting Manager for StageBio, she is responsible for all aspects of the company’s accounting functions and financial reporting. She has exceptional client relations skills and is committed to serving StageBio’s clients with excellence and friendliness.

Renee graduated with an accounting degree from Concordia College in Moorhead, Minnesota.